Denali Therapeutics (DNLI) Income from Continuing Operations: 2017-2024
Historic Income from Continuing Operations for Denali Therapeutics (DNLI) over the last 8 years, with Dec 2024 value amounting to -$114.7 million.
- Denali Therapeutics' Income from Continuing Operations rose 4.01% to -$114.7 million in Q4 2024 from the same period last year, while for Dec 2024 it was -$422.7 million, marking a year-over-year increase of 3.58%. This contributed to the annual value of -$422.8 million for FY2024, which is 191.12% down from last year.
- Per Denali Therapeutics' latest filing, its Income from Continuing Operations stood at -$114.7 million for Q4 2024, which was down 6.99% from -$107.2 million recorded in Q3 2024.
- Denali Therapeutics' 5-year Income from Continuing Operations high stood at $244.9 million for Q4 2020, and its period low was -$119.5 million during Q4 2023.
- Over the past 3 years, Denali Therapeutics' median Income from Continuing Operations value was -$102.6 million (recorded in 2022), while the average stood at -$99.6 million.
- As far as peak fluctuations go, Denali Therapeutics' Income from Continuing Operations surged by 553.28% in 2020, and later crashed by 130.73% in 2021.
- Denali Therapeutics' Income from Continuing Operations (Quarterly) stood at $244.9 million in 2020, then slumped by 130.73% to -$75.3 million in 2021, then plummeted by 31.11% to -$98.7 million in 2022, then decreased by 21.07% to -$119.5 million in 2023, then increased by 4.01% to -$114.7 million in 2024.
- Its Income from Continuing Operations stands at -$114.7 million for Q4 2024, versus -$107.2 million for Q3 2024 and -$99.0 million for Q2 2024.